Congenital Myasthenic Syndrome (CMS) Cell Models for Research

Congenital myasthenic syndromes (CMS) are a group of inherited disorders affecting the neuromuscular junction (NMJ), with an estimated prevalence of 1-9 per 1,000,000 individuals worldwide (Orphanet, 2023). The incidence varies by population, with higher rates in regions with consanguinity. CMS typically presents in infancy or early childhood with fatigable muscle weakness, ptosis, and bulbar dysfunction. Unlike autoimmune myasthenia gravis, CMS is not autoimmune and does not respond to immunosuppressive therapy. The mortality rate is low with early diagnosis and appropriate treatment, but delayed diagnosis can lead to respiratory failure and significant morbidity. According to the National Center for Advancing Translational Sciences (NCATS), the prognosis depends on the specific genetic subtype; some forms are mild and stable, while others, such as those with AChR deficiency, can be progressive. There is no cure, and management focuses on symptomatic treatment with acetylcholinesterase inhibitors, 3,4-diaminopyridine, or beta-adrenergic agonists, depending on the subtype. The quality of life for patients and families is significantly impacted, underscoring the need for targeted therapies.

CMS is an ideal model for studying synaptic transmission and NMJ assembly because it is a monogenic disorder with well-defined genetic subtypes. Over 30 genes have been implicated, including CHRNE, RAPSN, COLQ, AGRN, DOK7, and MUSK (NCBI Gene). These genes encode proteins essential for acetylcholine receptor (AChR) clustering, synaptic basal lamina formation, and endplate development. Public datasets such as ClinVar and UniProt provide comprehensive mutation and protein structure information, enabling precise modeling. Key open questions include the molecular mechanisms of synaptic stability, the role of glycosylation in AChR function, and the development of mutation-specific therapies. Gene-edited cell models allow researchers to dissect these pathways and test targeted interventions.

CMS is not a cancer, but the molecular pathways disrupted are critical for neuromuscular junction formation and function. The major pathways include:

1. AChR clustering and stabilization pathway:

• • Agrin secreted by motor neurons binds to LRP4, activating MUSK.
• • MUSK phosphorylates RAPSN and DOK7, leading to AChR clustering via rapsyn.
• • Defects in AGRN, LRP4, MUSK, RAPSN, or DOK7 cause CMS.

2. Synaptic basal lamina and acetylcholinesterase (AChE) pathway:

• • COLQ anchors AChE to the synaptic basal lamina.
• • Mutations in COLQ lead to endplate AChE deficiency, prolonged acetylcholine exposure, and receptor desensitization.

3. Glycosylation and AChR assembly pathway:

• • CHRNE, CHRNA1, CHRNB1, CHRND encode AChR subunits.
• • Mutations impair subunit assembly, trafficking, or glycosylation, reducing AChR number at the endplate.

4. Presynaptic vesicle release pathway:

• • Genes such as CHAT, SLC5A7, and SYT2 affect acetylcholine synthesis and release.
• • Defects cause presynaptic CMS with reduced quantal release.

The following table summarizes the most common genetic alterations in CMS, based on ClinVar and published cohorts. Frequencies are approximate and vary by population.

Data compiled from ClinVar (2024) and NCBI Gene.

The key signaling networks disrupted in CMS include:

• • Agrin-LRP4-MUSK pathway:
• • Agrin binds LRP4, activating MUSK.
• • MUSK phosphorylates rapsyn and DOK7, leading to AChR clustering.
• • Mutations in AGRN, LRP4, MUSK, or DOK7 disrupt this cascade.
• • Rapsyn-AChR clustering pathway:
• • Rapsyn links AChR to the cytoskeleton and is essential for clustering.
• • RAPSN mutations impair clustering and cause AChR deficiency.
• • Glycosylation pathway:
• • GFPT1 and DPAGT1 are involved in protein glycosylation.
• • Defects lead to abnormal AChR and AChE function.
• • Presynaptic release machinery:
• • CHAT and SLC5A7 regulate ACh synthesis and uptake.
• • SYT2 and other SNARE proteins affect vesicle fusion.
• • Endplate stability and maintenance:
• • COLQ anchors AChE; mutations cause prolonged ACh action.
• • AGRN and MUSK also maintain synaptic structure.

Immortalized cell lines and patient-derived organoids are valuable for CMS research. However, few stable CMS cell lines exist, and most studies use heterologous expression systems.

Organoids: Induced pluripotent stem cell (iPSC)-derived organoids and 3D neuromuscular junction models are emerging. These models recapitulate NMJ formation and can be gene-edited to introduce CMS mutations, offering a more physiologically relevant platform for drug testing.

Animal models of CMS include:

• • Knockout mice:
• • Chrne-/- mice exhibit severe AChR deficiency and die perinatally.
• • Rapsn-/- mice show defective AChR clustering and die at birth.
• • Colq-/- mice have AChE deficiency and survive to adulthood with weakness.
• • Knock-in mice:
• • Mice carrying the human N88K RAPSN mutation show mild CMS phenotypes.
• • Dok7 knock-in models display limb-girdle weakness.
• • Zebrafish models:
• • Zebrafish with mutations in agrn, musk, or rapsn show impaired swimming and NMJ defects.
• • Induced models:
• • Patient-derived iPSCs differentiated into motor neurons and myotubes can form NMJs in vitro.

These models are used to study pathogenesis and test therapeutic compounds, but species differences limit translation.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines carrying specific CMS mutations. These models are invaluable for studying disease mechanisms and drug responses.

• • Examples:
• • CHRNE knockout in HEK293 or C2C12 cells to model AChR deficiency.
• • RAPSN N88K knock-in in C2C12 myoblasts to study AChR clustering defects.
• • COLQ knockout in NSC-34 motor neurons to investigate AChE deficiency.
• • AGRN knockout in iPSC-derived motor neurons to disrupt NMJ formation.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent, reproducible platforms. These models can be used for high-throughput screening and target validation. Custom gene editing services can generate patient-specific mutations in relevant cell types, enabling precision medicine approaches.

Gene-edited cell models allow functional validation of CMS-associated genes. For example:

• • Knockout of CHRNE in myotubes confirms its role in AChR assembly and synaptic transmission.
• • Knock-in of the RAPSN N88K mutation demonstrates impaired clustering and reduced AChR density.
• • CRISPR screens can identify modifier genes that exacerbate or ameliorate CMS phenotypes.

These studies provide mechanistic insights and potential therapeutic targets.

Isogenic pairs of CMS mutant and corrected cells enable high-throughput drug screening. For example:

• • A CHRNE knockout cell line can be used to test drugs that enhance AChR expression or function.
• • A COLQ knockout model can screen for compounds that compensate for AChE deficiency.
• • Resistance modeling: gene-edited cells can be exposed to candidate drugs to identify resistance mechanisms, such as upregulation of compensatory pathways.

These applications accelerate preclinical drug development.

CRISPR-based synthetic lethality screens in CMS models can uncover biomarkers. For instance:

• • Genome-wide knockout screens in RAPSN mutant cells can identify genes whose loss rescues the phenotype.
• • Proteomic analysis of gene-edited cells can reveal dysregulated proteins as candidate biomarkers.
• • These biomarkers can be used for diagnosis, prognosis, and monitoring treatment response.